Biospring
also invests · investor profileFounded 2020 · 13 employees on LinkedIn · 1 known investors
Biospring is an investment firm that partners with technology-enabled, EBITDA-positive pharma services businesses focused on manufacturing and clinical trial services. Its portfolio companies produce and support the supply chain for complex medicines such as biologics, cell therapies, and peptides, and modernize clinical trial site operations, patient recruitment, and related technology for the life sciences industry.
Also known as Biospring Partners
Investors · 1
Company profile
researched Aug 2026Biospring is an investment firm focused on building businesses in the pharma services sector. It partners with technology-enabled, EBITDA-positive companies operating in pharmaceutical manufacturing and clinical trial services, positioning itself around long-term business building rather than early-stage venture backing.
The firm organizes its activity around three investment themes. Outsourced complex biomanufacturing covers companies that manufacture and support the supply chain for complex medicines, including biologics, bioconjugates, cell therapies and peptides, with sub-themes in outsourced biologics manufacturing and outsourced cell therapy manufacturing. Outsourced clinical trial services covers companies modernizing the clinical trial workflow through site operations, patient recruitment, participant access and purpose-built technology, including clinical trial site networks and a digitized pathology platform for clinical trials. A digital transformation theme covers a lab procurement platform and marketplace for R&D and a direct-to-patient platform for pharma.
Business model
Biospring invests in and partners with operating companies in pharma services, targeting businesses that are already EBITDA-positive and technology-enabled. It maintains a portfolio of companies across biomanufacturing, clinical trial services and digital transformation themes, and provides an LP login for limited partners.
Traction
Biospring's portfolio spans outsourced biologics manufacturing, outsourced cell therapy manufacturing, clinical trial site networks, a digitized pathology platform for clinical trials, a lab procurement platform and marketplace for R&D, and a direct-to-patient platform for pharma. Portfolio and platform names appearing in its news activity include Kiniciti, Cellistic, Ncardia, Cedar Health and PathAI.
Latest developments
In May 2026, Biospring reported that Roche had entered into a definitive merger agreement to acquire PathAI. The firm also hosted a webinar in May 2026 on induced pluripotent stem cells with Kiniciti, Cellistic and Ncardia, and a webinar in July 2026 on community-focused clinical research with Cedar Health and Amgen.
▸Full profile — market position, go-to-market
Market position
Biospring positions itself as an investor in the pharma services value chain, spanning outsourced complex biomanufacturing, outsourced clinical trial services and digital transformation of life sciences workflows.
Go-to-market
Biospring's portfolio companies serve the life sciences industry, including pharmaceutical and biotech sponsors requiring outsourced manufacturing of complex medicines, clinical trial sponsors and sites, R&D laboratories, and ultimately patients participating in clinical research.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsBiospring hosted a webinar on community-focused clinical research with Cedar Health and Amgen.
Biospring hosted a webinar on induced pluripotent stem cells featuring Kiniciti, Cellistic and Ncardia.
Biospring's news feed reports that Roche entered into a definitive merger agreement to acquire PathAI, described in the context of AI-driven diagnostics.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Biospringbiospring.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Biospring do?
- Biospring is an investment firm backing technology-enabled, EBITDA-positive pharma services businesses.
- Who are Biospring's investors?
- Biospring's investors include Atento Capital.